此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Selection of Transcatheter Heart vaLve With Intermediate Sizing in Patients With Severe Aortic Stenosis Treated With Transcatheter Aortic Valve Replacement (SELECT TAVR)

Selection of transcathEter Heart vaLve With intermEdiate Sizing in Patients With Severe aortiC Stenosis Treated With Transcatheter Aortic Valve Replacement

Transcatheter aortic valve implantation (TAVI) has evolved into a standard therapy for severe aortic stenosis across all surgical risk profiles, supported by pivotal trials in high- and low-risk populations. Two types of transcatheter heart valves, balloon-expandable and self-expanding, exhibit distinct hemodynamic and structural characteristics that influence procedural strategy and long-term durability. Accurate valve sizing is crucial for procedural success, as both undersizing and oversizing are associated with procedural complications, including aortic regurgitation, conduction disorders, valve embolization, annular rupture, and increased leaflet stress which may impair long-term durability. However, optimal annular sizing remains challenging due to the complex three-dimensional anatomy of the aortic annulus, which is oval, crown-shaped, dynamically deforming, and variably oriented. These anatomical features often lead to "grey zones" in clinical sizing charts, resulting in so-called borderline annuli in which the measured annular dimensions may indicate two suitable valve sizes. Borderline annuli are frequently encountered in patients undergoing TAVI with self-expanding valves (i.e., Evolut transcatheter heart valve series) due to a limited number of sizes (23, 26, 29 and 34 mm). Consequently, under- or oversizing of self-expanding valves is often required. However, sizing of transcatheter heart valves in borderline annuli is associated with a greater likelihood of procedural complications, higher rates of aortic regurgitation, and higher transvalvular gradients.9,11 New generation balloon-expandable valves (i.e., Myval transcatheter heart valve series) are introduced with intermediate (21.5, 24.5, 27.5 mm) and extra-large (30.5, 32 mm) valve sizes that are not available for the Evolut platform. These additional size ranges potentially offer more precise annular sizing, reducing the need for under- or oversizing and improving short- and long-term hemodynamic performance.

The SELECT TAVR trial will evaluate whether the expanded size range of the balloon-expandable Myval transcatheter heart valves is noninferior compared to the self-expanding Evolut transcatheter heart valve series in patients with borderline annular dimensions undergoing TAVI with respect to the composite safety end point of the third Valve Academic Research Consortium (VARC-3) at 30 days.

Objectives:

The primary objective of the current trial is to determine whether the Myval transcatheter heart valve series is noninferior to the Evolut transcatheter heart valve series in patients with borderline annular dimensions undergoing TAVI with respect to the composite safety end point of the third Valve Academic Research Consortium (VARC-3) at 30 days Secondary objectives: The secondary objectives of the current trial include: 1) Hemodynamic performance as assessed by invasive hemodynamic parameters as well as by transthoracic echocardiography at 30 days (+2 months), and longer-term follow-up; and 2) Long-term clinical outcomes with follow-up up to 5 years.

Study design:

The proposed SELECT TAVR trial is an investigator-initiated, open-label, multicenter, randomized controlled, noninferiority trial with blind end point adjudication.

Study population:

The SELECT TAVR trial will focus on patients referred for TAVI in whom CT-derived annular dimensions fall within borderline annulus ranges

研究概览

地位

尚未招聘

研究类型

介入性

注册 (估计的)

604

阶段

  • 第四阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

A potential participant is deemed eligible for trial participation if the following criteria are met:

  1. TAVI as decided by local multidisciplinary heart team
  2. CT-derived annular perimeters fall within the following ranges:

    • 55.5 - 57.5 mm
    • 61.0 - 64.5 mm
    • 70.5 - 74.0 mm
    • 79.5 - 84.0 mm
    • 92.0 - 96.0 mm
  3. Written informed consent

Exclusion Criteria:

A potential participant will be excluded from trial participation in case of inability to provide informed consent.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
有源比较器:Self-expanding Evolut transcatheter heart valve series
All subjects undergo transcatheter aortic valve implantation because of symptomatic severe aortic valve stenosis. This is a routine medical procedure, not a study intervention.
其他名称:
  • TAVI
  • TAVR
  • 经导管主动脉瓣植入术
  • 经导管主动脉瓣置换术
实验性的:Balloon-expandable Myval transcatheter heart valve series
All subjects undergo transcatheter aortic valve implantation because of symptomatic severe aortic valve stenosis. This is a routine medical procedure, not a study intervention.
其他名称:
  • TAVI
  • TAVR
  • 经导管主动脉瓣植入术
  • 经导管主动脉瓣置换术

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
A composite safety end point as per VARC-3 guidelines
大体时间:30 days
A composite safety end point as per VARC-3 guidelines that consists of all-cause mortality, all stroke, type 2 to 4 bleeding, major vascular access-related or cardiac structural complications, acute kidney injury stage 3 to 4, moderate or severe aortic regurgitation, new permanent pacemaker implantation due to conduction abnormalities, surgery or intervention related to the device at 30 days after TAVI as defined in accordance with criteria stated by the third Valve Academic Research Consortium (VARC-3).
30 days

次要结果测量

结果测量
措施说明
大体时间
A composite safety endpoint as per VARC-3 guidelines
大体时间:Annually, up to 5 years
All clinical end points will be assessed after TAVI
Annually, up to 5 years
Hemodynamic performance
大体时间:At 30 days (+2 months) and at 1, 3 and 5 years
Hemodynamic performance will be assessed by transthoracic echocardiography
At 30 days (+2 months) and at 1, 3 and 5 years
Patient-reported outcomes, using the Kansas City Cardiomyopathy Questionnaire (KCCQ)-12
大体时间:Yearly, up to 5 years
Yearly, up to 5 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Ronak Delewi, Prof. Dr.、Amsterdam University Medical Center

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年8月1日

初级完成 (估计的)

2033年8月1日

研究完成 (估计的)

2033年8月1日

研究注册日期

首次提交

2026年7月1日

首先提交符合 QC 标准的

2026年7月1日

首次发布 (实际的)

2026年7月8日

研究记录更新

最后更新发布 (实际的)

2026年7月8日

上次提交的符合 QC 标准的更新

2026年7月1日

最后验证

2026年7月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅